Lawyer profile for UK 2021
Chambers Research is conducted by 200 Research Analysts, across 200 jurisdictions and provides nearly 6,000 rankings tables. Annually we collect hundreds of thousands of responses from clients, the majority via in-depth interview. Learn more about our methodology.
Private Equity: Venture Capital Investment - UK-wide
This content is provided by David Mardle
David Mardle is a partner in Goodwin’s Technology and Life Sciences group with 20 years of experience advising on financings and M&A transactions in the life sciences and technology sectors. Leveraging his significant M&A experience combined with his general corporate and capital markets expertise, Mr. Mardle now concentrates his focus on representing emerging biotech companies providing counsel on corporate and capital markets transactions.
Prior to joining Goodwin in 2019, Mr. Mardle was a partner at Taylor Wessing LLP.
Mr. Mardle serves as secretary to Cambridge Network, a networking organization for business people and academics working in technology fields in the Cambridge area of the UK. The businesses and organizations that make up its membership are typical of those found in the “Cambridge Cluster” or Silicon Fen. Mr. Mardle is also a member of the working group of the British Venture Capital Association for the model documents for equity investment transactions.